In this article, we will list the 5 Set-It-and-Forget-It Stocks to Buy in 2026. Please visit 15 Set-It-and-Forget-It Stocks to Buy in 2026 if you’d like to see the extended list and the methodology behind it.
5. Monster Beverage Corporation (NASDAQ:MNST)
Number of Hedge Fund Holders: 59
Monster Beverage Corporation (NASDAQ:MNST) is one of the 15 set-it-and-forget-it stocks to buy in 2026.
On March 16, 2026, Monster Beverage Corporation (NASDAQ:MNST)’s price target from Wells Fargo was lowered from $94 to $90. Wells Fargo analyst kept an Overweight rating on the stock. The firm maintains a positive outlook on Monster Beverage Corporation (NASDAQ:MNST) amid post-earnings stock declines and concerns over growth deceleration. Following a sales analysis, analysts believe growth remains durable with catalysts ahead.
In another development, on March 11, 2026, Jefferies maintained a Buy rating on Monster Beverage Corporation (NASDAQ:MNST) while keeping its price target at $100. The firm characterized the recent 11% share decline as a buying opportunity. Jefferies attributes the pullback to “near-term noise,” including increases in gas prices, market share gains by Red Bull, and geopolitical uncertainty. However, amid these headwinds, the firm expresses confidence in the company’s long-term fundamentals. It cited resilient U.S. energy category and new food service avenues in addition to international and affordable initiatives as growth drivers that are anticipated to provide incremental upside.
Founded in 1985, Monster Beverage Corporation (NASDAQ:MNST) is an American beverage company that operates through brands such as Monster Energy, Reign, and Bang to develop, market, sell, and distribute energy drinks. Its headquarters is in California.
4. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Number of Hedge Fund Holders: 64
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 15 set-it-and-forget-it stocks to buy in 2026.
On March 19, 2026, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) saw its price target raised by Wells Fargo from $515 to $550. The firm’s analyst kept an Overweight rating on the shares. Wells Fargo anticipates a threefold growth in the market for the generalized Myasthenia Gravis (gMG), reaching $20 billion globally by 2036. Analysts cite new drugs and mechanisms, such as CD20, BAFF/APRILs, and next-generation complement inhibitors, as significant drivers of growth. The firm identifies Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Amgen (AMGN), and Regeneron (REGN) as the key beneficiaries of this growth, while expressing a notable belief in an upside to current Wall Street estimates.
In a separate event, on March 18, 2026, Maxim upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to Buy and maintained a $575 price target. According to the firm, Povetacicept has the potential to be a blockbuster with “pipeline-in-a-product” capabilities. The analyst further noted that, alongside Journavx and Casgevy, the company has three products that provide crucial diversification beyond its cystic fibrosis franchise.
Founded in 1989, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company. Based in Massachusetts, the company develops and commercializes therapies for serious diseases, with a primary focus on cystic fibrosis and genetic disorders.
3. United Therapeutics Corporation (NASDAQ:UTHR)
Number of Hedge Fund Holders: 68
United Therapeutics Corporation (NASDAQ:UTHR) is one of the 15 set-it-and-forget-it stocks to buy in 2026.
On March 12, 2026, Cantor Fitzgerald raised its price target on United Therapeutics Corporation (NASDAQ:UTHR) from $525 to $625 and maintained an Overweight rating on the stock. According to the analyst, the idiopathic pulmonary fibrosis remains the company’s top investment catalyst. The firm noted that if the TETON-1 clinical trial delivers expected results, the stock will see significant upside, with its per-share value reaching over $600 in the coming months. It will also strengthen the company’s leadership in treating this critical lung condition.
Separately, on March 9, 2026, United Therapeutics Corporation (NASDAQ:UTHR) authorized a new $2 billion stock repurchase program. The company launched an initial $1.5 billion accelerated share repurchase (ASR) via agreements with Citibank. This includes both collared and uncollared structures. As part of the agreement, the company made an upfront payment on March 11, which was immediately followed by the delivery of approximately 50% to 70% of the anticipated shares under the collared and uncollared ASR agreement. The remaining $500 million remains available for discretionary buybacks over a 1-year period.
Founded in 1996, United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company focused on rare lung diseases. Headquartered in Silver Spring, Maryland, the company develops pharmaceuticals and technologies related to organ transplantation.
2. The Progressive Corporation (NYSE:PGR)
Number of Hedge Fund Holders: 82
The Progressive Corporation (NYSE:PGR) is one of the 15 set-it-and-forget-it stocks to buy in 2026.
On March 20, 2026, Mizuho lowered its price target on The Progressive Corporation (NYSE:PGR) from $235 to $223. The firm’s analyst kept a Neutral rating on the shares.
Prior to this update, on March 18, 2026, the company reported its earnings for the month ended February 28, 2026, where The Progressive Corporation (NYSE:PGR) highlighted a 2% increase in monthly net income, reaching $943 million. Total policies in force grew 10% year-over-year to 39.2 million. The growth was partially attributed to a 14% surge in Direct auto policies. However, the company’s combined ratio went up from 82.6 to 85.7 in 2025, indicating higher underwriting costs. Additionally, the company noted in its monthly commentary that a monthly closing nuance lowered companywide net premiums written growth by 2-3 percentage points for February. The management expects the March premium growth rate to climb by a similar amount, leaving overall first-quarter growth results unaffected.
Founded in 1937, The Progressive Corporation (NYSE:PGR) is an American insurance holding company specializing in personal and commercial auto, homeowners, and specialty property-casualty insurance. The company’s headquarters is in Ohio.
1. ServiceNow, Inc. (NYSE:NOW)
Number of Hedge Fund Holders: 118
ServiceNow, Inc. (NYSE:NOW) is one of the 15 set-it-and-forget-it stocks to buy in 2026.
On March 10, 2026, Rothschild & Co Redburn lowered the price target on ServiceNow, Inc. (NYSE:NOW) from $230 to $215 while maintaining a Buy rating on the company’s stock. The firm’s analyst noted that ServiceNow, Inc. (NYSE:NOW)’s extensive platform integrations, IT workflow knowledge graph, and unique configuration database create a significant competitive moat, making it resilient against any changes in the AI market.
Separately from this update, on March 16, 2026, ServiceNow, Inc. (NYSE:NOW) announced an expansion in its partnership with Carahsoft Technology Corp. The expanded collaboration involves extending the availability to the ServiceNow AI Platform across Carahsoft’s full reseller ecosystem in Canada and the U.S. According to Michael Park, senior vice president, Global Partnerships and Channels, ServiceNow, Inc. (NYSE:NOW), the expanded partnership with Carahsoft enable the company to reach more customers beyond the Government IT sector and into healthcare, financial services, critical infrastructure, and enterprise markets through Carahsoft’s reseller ecosystem.
Founded in 2004, ServiceNow, Inc. (NYSE:NOW) is a leading American cloud-based software company that provides a global cloud computing platform that automates enterprise workflows for IT, HR, and customer service. The company’s headquarters is located in California.
While we acknowledge the potential of NOW to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NOW and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Space Exploration Stocks to Buy According to Analysts and 10 Best Diagnostics and Research Stocks to Buy According to Analysts
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
